Monthly Archives - September 2021

Canvas GFX and Aras partner to deliver integration of Aras Innovator and Canvas Envision

Canvas GFX, Inc, the leading provider of visual communication solutions to the manufacturing and technical industries today announced that it has partnered with Aras, provider of a digital transformation platform to enable the resilient enterprise to deliver an integration between Canvas Envision and the Aras innovator platform. The integration enables end users to access data stored on Aras Innovator directly from the Envision Creator desktop graphics application, allowing frictionless creation of product documentation containing rich visualizations of 3D models. […]

Myomo, Inc. Announces Granting of Patents in China and Hong Kong

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the granting of patents in China and Hong Kong covering the Company’s most advanced products. The patents are titled “Powered Orthotic Device and Method of Using Same,” which cover a powered orthotic device that supports movement of a user’s arm about the elbow and a user’s fingers and thumb to support grasping. These newly issued patents are […]

Taiwania Capital Joins Pool of Existing Investors to Fund $17 Million of Series B-1 Investment in Novel Drug Delivery Company, Windgap Medical, Inc.

Windgap Medical, Inc., a leading drug delivery platform company, announced today that it has successfully completed initial closing of over $17 million of Series B-1 equity financing round of investment, led by Taiwania Capital. This equity investment round is also supported by existing investors, including Shepherd Kaplan Krochuk, Molex Ventures (a Koch Industries company), and others. Read more >>

Second-generation vaccines offer a chance to correct flaws in early vaccination campaigns

…The vaccine candidate known as AKS-452, from Massachusetts-based Akston Biosciences, is one promising example of a jab which could address vaccine inequity and vaccine hesitancy alike. Following promising Phase I trial data which found that AKS-452 was safe, well-tolerated, and achieved a 100% seroconversion rate even after a single 90 µg dose, the vaccine candidate is now undergoing Phase II trials in the University Medical Center Groningen (UMCG) in the Netherlands. Read more >>

Astrocyte Pharmaceuticals Awarded Major Grant to Further Develop Promising Treatment for Brain Injury

Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, announced today that it has received a $500,000 award jointly funded by the Medical Technology Enterprise Consortium (MTEC) and the BrightFocus Foundation. Read more >>

Myomo’s Wearable Completes First Phase of Brain-Computer Interface Trial

Massachusetts medical robotics provider Myomo has developed MyoPro wearable to offer enhanced functionality to patients with neurological disorders and upper-limb paralysis. It has recently announced that Thomas Jefferson University has conducted the first phase of clinical trials leveraging sensors embedded in the brain to control a MyoPro-boosted brace worn by a stroke patient. Read more >>

NEXT Venture Pitch finalists

…Billed as the “premiere venture pitch of the Carolinas,” NEXT gives entrepreneurs a chance to pitch ideas to investors, venture capitalists and community leaders. One of the six finalists is: Zylö Therapeutics — Next-gen, topical drug delivery systems. Read more >>

Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute

Xylyx Bio, Inc., a biotechnology company developing groundbreaking solutions for drug discovery and tissue modeling and repair, announced today that it has been awarded a Small Business Innovation Research (SBIR) Fast-Track grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to advance development of an anti-fibrotic drug testing platform that will help scientists discover and test drug candidates for idiopathic pulmonary fibrosis (IPF). Read more >>